Display Settings:

Format

Send to:

Choose Destination
Hematol Oncol Clin North Am. 2011 Dec;25(6):1215-33, viii. doi: 10.1016/j.hoc.2011.10.002.

Curing all patients with acute promyelocytic leukemia: are we there yet?

Author information

  • 1Department of Medicine, New York-Presbyterian Hospital/Weill Cornell Medical Center, 525 East 68th Street, Box 130, New York, NY 10065, USA.

Abstract

The introduction of all-trans retinoic acid to anthracycline-based chemotherapy has revolutionized the prognosis of patients with acute promyelocytic leukemia (APL). The introduction of arsenic trioxide enabled the therapeutic approach of rationally targeted frontline protocols with minimal or no traditional cytotoxic chemotherapy and without compromise of previously established outstanding outcomes with anthracycline-based regimens. Although most of the current investigative efforts in APL are focused on developing potentially curative therapy without the exposure to toxicities and risks of DNA-disrupting agents, the cure rate can further be increased by implementing meticulous supportive care strategies that counter early coagulopathy-related deaths.

Copyright © 2011 Elsevier Inc. All rights reserved.

PMID:
22093584
[PubMed - indexed for MEDLINE]
PMCID:
PMC4021483
Free PMC Article

Images from this publication.See all images (2)Free text

Fig. 1
Fig. 2
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Write to the Help Desk